Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer TherapyGlobeNewsWire • 01/05/26
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewsWire • 11/25/25
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains MomentumGlobeNewsWire • 11/06/25
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA TrialGlobeNewsWire • 11/06/25
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation ConferenceGlobeNewsWire • 11/04/25
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025GlobeNewsWire • 10/30/25
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/29/25
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026GlobeNewsWire • 10/27/25
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder CancerGlobeNewsWire • 10/02/25
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial ResultsGlobeNewsWire • 08/07/25
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder CancerGlobeNewsWire • 08/05/25
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025GlobeNewsWire • 07/29/25
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action LawsuitGlobeNewsWire • 07/28/25
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in UrologyGlobeNewsWire • 07/28/25
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action LawsuitGlobeNewsWire • 07/21/25
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. (URGN) Class Action – Investors With Significant Losses Encouraged to Contact the FirmGlobeNewsWire • 07/21/25